Boston Therapeutics Inc. BTHE Archives

FridayDec 27, 2013 4:06 pm

Pivotal Phase 3 Trial a Key Objective for Boston Therapeutics (BTHE) in 2014

Boston Therapeutics is a pharmaceutical company using complex carbohydrate chemistry to advance its PAZ320 and IPOXYN drug candidates for the treatment of Type 2 diabetes. With 2013 under wraps, BTHE looks to have an exciting first half of the upcoming year. In mid-2014, BTHE hopes to start a pivotal phase 3 study of PAZ320, a chewable tablet to be taken before meals to reduce post-meal elevation of blood glucose in Type 2 diabetics by blocking the action of carbohydrate-hydrolyzing enzymes. The two-year study, to be conducted in the U.S., Europe, Hong Kong, Korea, and China, will evaluate the effects of…

TuesdayDec 17, 2013 4:54 pm

Boston Therapeutics, Inc. (BTHE) is Creating a Better Drug to Prevent and Treat Diabetes

In the United States alone, an estimated 26 million people have Type 2 diabetes while another 80 million or so people are pre-diabetic. Recognizing that there are urgent, unfulfilled medical needs for both the pre-diabetic and diabetic community, Boston Therapeutics is concentrating on creating better technology to prevent diabetes and its complications. Considering the varied and dangerous complications that stem from uncontrolled diabetes (such as heart disease, stroke, and kidney damage), Boston Therapeutics’ goal is to better control glucose levels in patients throughout the day using innovations in complex carbohydrate chemistry. The key diabetic solution in the company’s arsenal is…

TuesdayDec 10, 2013 9:34 am

Boston Therapeutics, Inc. (BTHE) Announces Three Management Appointments

Boston Therapeutics, an innovator of drugs that target diabetes using complex carbohydrate chemistry, today announced the appointment of three management positions within its ranks. Effective immediately, Edward Shea will serve as Vice President Business Development, Tina M. Gagnon will serve as Consulting Director of Finance, and Yael T. Bobruff, Ph.D. will serve as Clinical Affairs Manager, respectively. David Platt, Ph.D., Chief Executive Officer, Boston Therapeutics, said, "As Boston Therapeutics enters the next phase of its growth, it is imperative that we attract top talent to help us advance and commercialize our drug development programs. Ed Shea and Tina Gagnon's business…

MondayDec 09, 2013 2:00 pm

Boston Therapeutics, Inc. (BTHE) Takes Firm Stance Against Type 2 Diabetes, Backed by High-Potential Candidate Pipeline

Boston Therapeutics is developing a pipeline of therapeutic molecules based on complex carbohydrate chemistry. This pipeline currently carries three compounds that are being fine-tuned and tested in hopes that each will become a commercialized therapeutic treatment for diabetes. Drug candidate PAZ320 is being developed for the prevention of diabetes and related complications. PAZ320 is a non-systemic, non-toxic, chewable drug candidate that inhibits the enzymes that release glucose from complex carbohydrates in foods during digestion. By blocking this release, the drug reduces the amount of available glucose absorbed through the intestine. The company recently began enrollment for phase IIb trial in…

MondayDec 09, 2013 11:26 am

Boston Therapeutics, Inc. (BTHE) Receives Positive Highlight at Seeking Alpha

In an article published recently on Seeking Alpha, Boston Therapeutics was highlighted as a biopharmaceutical company with promising investor potential. The article pointed to factors such as the company’s potentially “blockbuster” treatment for diabetes and its experienced management as reasons for its growing attractiveness among biomedical stocks. The article also made note of Boston Therapeutics’ founder, chairman, and CEO, Dr. David Platt, and his focused mission on reversing the onset of diabetes globally. Dr. Platt’s determination to slow, if not reverse, the onset of diabetes seems well-grounded. According to the World Health Organization, in just 2000 177 million people worldwide…

MondayNov 25, 2013 4:45 pm

Boston Therapeutics, Inc. (BTHE) on Accelerated Path for Drug Development

Boston Therapeutics is a pharmaceutical company focused on the development and commercialization of novel compounds based on complex carbohydrate chemistry to address unmet medical needs. The company’s current product pipeline is focused on developing and commercializing the therapeutic molecules PAZ320 for patients with diabetes; and Ipoxyn™ for a wide rand of indications such as anemia and blood loss (injury), cardiovascular disease, and surgical blood supplementation. The company’s lead product, PAZ320, is a non-systemic, non-toxic, chewable drug candidate that inhibits the enzymes that release glucose from complex carbohydrate in foods during digestion. Boston Therapeutics has developed the PAZ320 drug compound for…

MondayNov 18, 2013 9:31 am

Boston Therapeutics, Inc. (BTHE) Presenting at Elsevier Therapeutic Area Partnerships 2013 Conference

Boston Therapeutics, a company focusing on the development of diabetes treatments using complex carbohydrate chemistry, continues to make progress in raising public awareness of its diabetes drug’s potential. The company announced in a news release today it will be presenting at the Elsevier Therapeutic Area Partnerships 2013 Conference, where it was selected as one of 10 “Top Projects to Watch” within the category of cardiovascular/metabolic diseases. Mr. Kenneth A. Tassey, Jr., President of Boston Therapeutics, will be presenting information about the diabetes drug PAZ320 at the conference. From 2:15 to 3:05 PM on Tuesday, November 19, 2013, at the Hyatt…

ThursdayNov 14, 2013 9:42 am

Boston Therapeutics, Inc. (BTHE) Exhibiting PAZ320 at Inaugural Obesity Week 2013 Conference

Boston Therapeutics, a company focusing on the development of drugs using complex carbohydrate chemistry to address diabetes, reported in a news release today it is an exhibitor at the inaugural Obesity Week 2013 Conference in Atlanta, Georgia. The conference, taking place November 13-15, is billed as the world’s largest event on preventing and treating obesity, gathering the world’s leading scientists, clinicians, and surgeons for collaboration, data presentation, and networking. At the conference, Boston Therapeutics will be in Booth #127, presenting information about its PAZ320, a non-systemic chewable tablet drug which targets enzymes that digest sugar during digestion. The drug therefore…

TuesdayNov 12, 2013 10:24 am

Boston Therapeutics, Inc. (BTHE) Begins Enrolling Patients in Phase 2b Trial for PAZ320

Boston Therapeutics announced it has begun enrolling patients in a Phase 2b Trial for its PAZ320 drug today. A total of 24 patients with type 2 diabetes currently being treated with metformin will be administered PAZ320 under double-blind, placebo-controlled conditions. The study is taking place at Centre Hospitalier Robert Bisson, Lisieux, France. Study performers will monitor the patients’ blood glucose using continuous glucose monitors, and their after-meal blood glucose levels measured using following a test meal. The primary endgoal of the trial is to evaluate the effect of PAZ320 compared to placebo the area under the curve (AUC) of glucose…

TuesdayNov 05, 2013 12:14 pm

Boston Therapeutics, Inc. (BTHE) – Could the Move Away from Fats be Contributing to Obesity?

Although the idea of low-fat diets has a long history, it really took off in the 1980s when major American medical studies came down hard on cholesterol and animal fats, causing a revolution in the marketing of food. Suddenly meat and eggs and butter and cheese were thrown under a huge cloud of suspicion in the mind of consumers as possible contributors to heart attacks and stroke, and an unprecedented shift in eating habits started to take shape across the country. It was a painful move for many, but the medical and media pressure continued, and millions began to look…

Site Search

Company Search

Tag: Boston Therapeutics Inc. BTHE